TW363969B - Galanthamine derivatives and their use as medicaments - Google Patents

Galanthamine derivatives and their use as medicaments

Info

Publication number
TW363969B
TW363969B TW083109526A TW83109526A TW363969B TW 363969 B TW363969 B TW 363969B TW 083109526 A TW083109526 A TW 083109526A TW 83109526 A TW83109526 A TW 83109526A TW 363969 B TW363969 B TW 363969B
Authority
TW
Taiwan
Prior art keywords
hydrogen
carbonyloxy
medicaments
halo
cycloalkyl
Prior art date
Application number
TW083109526A
Other languages
English (en)
Inventor
Raymond W Kosley
Larry Davis
Veronica Taberna
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Application granted granted Critical
Publication of TW363969B publication Critical patent/TW363969B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW083109526A 1993-10-15 1994-10-14 Galanthamine derivatives and their use as medicaments TW363969B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,440 US6323195B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (1)

Publication Number Publication Date
TW363969B true TW363969B (en) 1999-07-11

Family

ID=22477446

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083109526A TW363969B (en) 1993-10-15 1994-10-14 Galanthamine derivatives and their use as medicaments

Country Status (23)

Country Link
US (2) US6323195B1 (zh)
EP (2) EP1020470A3 (zh)
JP (1) JP2664344B2 (zh)
KR (1) KR0169114B1 (zh)
CN (1) CN1039911C (zh)
AT (1) ATE212348T1 (zh)
AU (1) AU696249B2 (zh)
CA (1) CA2118174C (zh)
CZ (1) CZ287071B6 (zh)
DE (1) DE69429708T2 (zh)
DK (1) DK0653427T3 (zh)
EG (1) EG20472A (zh)
ES (1) ES2171428T3 (zh)
FI (1) FI108723B (zh)
IL (1) IL111274A (zh)
NO (1) NO310415B1 (zh)
NZ (1) NZ264683A (zh)
PL (1) PL177730B1 (zh)
PT (1) PT653427E (zh)
RO (1) RO114133B1 (zh)
RU (1) RU2114850C1 (zh)
TW (1) TW363969B (zh)
ZA (1) ZA948062B (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP1133230A4 (en) * 1998-11-23 2004-05-26 Bonnie M Davis DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS
SK287676B6 (sk) 1998-12-24 2011-05-06 Janssen Pharmaceutica N. V. Prostriedok s riadeným uvoľňovaním obsahujúci galantamín, spôsob jeho prípravy, dávková forma a farmaceutické balenie s jeho obsahom a použitie galantamínu na výrobu tohto prostriedku
EP1150695B1 (en) * 1999-01-11 2007-02-28 Atanas Russinov Djananov Herbal supplement for increased muscle strength and endurance for athletes
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
ES2211056T3 (es) * 1999-03-31 2004-07-01 Eisai Co., Ltd. Composiciones estabilizadas que contienen farmacos nootropicos.
ES2250211T3 (es) * 1999-10-26 2006-04-16 Janssen Pharmaceutica N.V. Disolucion oral que contiene galantamina y un agente edulcorante.
WO2001043697A2 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
DE50101827D1 (de) 2000-03-31 2004-05-06 Sanochemia Pharmazeutika Ag Wi Neue derivate und analoga von galanthamin
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005065661A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galanthamine
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
EP1779867A4 (en) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
PL1895994T3 (pl) * 2005-05-13 2011-02-28 Alza Corp Wielowarstwowy system podawania leków z barierą zabezpieczającą przed wypływaniem materiału ze zbiornika
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
EP1777222A1 (en) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
ATE473219T1 (de) * 2005-09-22 2010-07-15 Galantos Pharma Gmbh Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
WO2009127218A1 (en) 2008-04-14 2009-10-22 Galantos Pharma Gmbh Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
US20120184532A1 (en) * 2009-07-23 2012-07-19 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
EP3628315A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
CN113292420A (zh) * 2021-05-27 2021-08-24 神隆医药（常熟）有限公司 加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
EP0363415B1 (en) * 1987-05-04 2008-10-15 Davis, Bonnie Compounds for the treatment of alzheimer's disease
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
WO1992020327A1 (en) 1991-05-14 1992-11-26 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
CA2118174C (en) 2000-01-18
EP0653427A1 (en) 1995-05-17
DK0653427T3 (da) 2002-04-15
IL111274A (en) 2000-11-21
ZA948062B (en) 1995-06-06
EG20472A (en) 1999-05-31
KR950011443A (ko) 1995-05-15
CZ287071B6 (en) 2000-08-16
ES2171428T3 (es) 2002-09-16
RO114133B1 (ro) 1999-01-29
RU2114850C1 (ru) 1998-07-10
PT653427E (pt) 2002-06-28
AU7581494A (en) 1995-05-04
CZ254694A3 (en) 1995-09-13
AU696249B2 (en) 1998-09-03
DE69429708D1 (de) 2002-03-14
PL177730B1 (pl) 2000-01-31
US5777108A (en) 1998-07-07
FI108723B (fi) 2002-03-15
CN1111245A (zh) 1995-11-08
NZ264683A (en) 1998-03-25
EP1020470A2 (en) 2000-07-19
EP1020470A3 (en) 2000-07-26
CA2118174A1 (en) 1995-04-16
RU94036448A (ru) 1996-09-10
ATE212348T1 (de) 2002-02-15
EP0653427B1 (en) 2002-01-23
KR0169114B1 (ko) 1999-01-15
JP2664344B2 (ja) 1997-10-15
FI944821A0 (fi) 1994-10-13
CN1039911C (zh) 1998-09-23
FI944821A (fi) 1995-04-16
IL111274A0 (en) 1994-12-29
NO943893D0 (no) 1994-10-14
PL305456A1 (en) 1995-04-18
NO943893L (no) 1995-04-18
JPH07188240A (ja) 1995-07-25
DE69429708T2 (de) 2002-08-29
US6323195B1 (en) 2001-11-27
NO310415B1 (no) 2001-07-02

Similar Documents

Publication Publication Date Title
TW363969B (en) Galanthamine derivatives and their use as medicaments
AU3677393A (en) 2-Oxoethyl derivatives as immunosuppressants
AU676884B2 (en) 1H-indole-3-acetamide sPLA2 inhibitors
AU7077894A (en) Immunosuppressant and antiallergic compounds, e.g. n-(3-oxohexanoyl) homoserine lactone
EP1288199A4 (en) INHIBITORS OF MMP-12
TW347387B (en) Piperidine derivatives
ATE183182T1 (de) S-triazinderivate als lichtschutzmittel
MY110191A (en) 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
MY131501A (en) Process for the prepration of clavulanic acid
GR3017243T3 (en) Antiemetic and migraine suppressing heterocyclic compounds and pharmaceutical compositions containing them.
AU7581294A (en) Galanthamine derivatives, a process for their preparation and their use as medicaments
AU4616893A (en) New benzopyran compounds, process for their preparation and the pharmaceutical compositions which contain them
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
AU7589494A (en) Pyrrolidine derivatives
GB9015485D0 (en) Heterocyclic derivatives
TW218379B (en) Hydroxymethylpolythiophene derivative
CA2117330A1 (en) The use of psoralen compounds to inhibit restenosis following angioplasty

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees